These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21132998)

  • 41. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Mult Scler; 2006 Jun; 12(3):281-6. PubMed ID: 16764340
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon Beta-1a and intravenous immunoglobulin treatment for multiple sclerosis in Iran.
    Kalanie H; Gharagozli K; Hemmatie A; Ghorbanie M; Kalanie AR
    Eur Neurol; 2004; 52(4):202-6. PubMed ID: 15539773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability.
    Vermersch P; de Seze J; Stojkovic T; Hautecoeur P;
    J Neurol; 2002 Feb; 249(2):184-7. PubMed ID: 11985384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis.
    Etemadifar M; Janghorbani M; Shaygannejad V
    J Neurol; 2007 Dec; 254(12):1723-8. PubMed ID: 18074075
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial.
    Mokhber N; Azarpazhooh A; Orouji E; Rao SM; Khorram B; Sahraian MA; Foroghipoor M; Gharavi MM; Kakhi S; Nikkhah K; Azarpazhooh MR
    J Neurol Sci; 2014 Jul; 342(1-2):16-20. PubMed ID: 24841321
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study.
    Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu G; Martinelli V; Milani N; Milanese C; Moiola L; Patti F; Pilato V; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Mult Scler; 2005 Aug; 11(4):420-4. PubMed ID: 16042224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
    Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.
    Vermersch P; de Seze J; Delisse B; Lemaire S; Stojkovic T
    Mult Scler; 2002 Oct; 8(5):377-81. PubMed ID: 12356203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
    Suljic E; Sinanovic O; Kurtovic-Alajbegovic A; Klupka-Saric I
    Med Arch; 2013; 67(3):178-80. PubMed ID: 23848037
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.
    Arababadi MK; Mosavi R; Khorramdelazad H; Yaghini N; Zarandi ER; Araste M; Pourali R; Nekhei Z; Kennedy D
    Biomark Med; 2010 Oct; 4(5):755-9. PubMed ID: 20945990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The results of longitudinal use of copaxone and betaferon in Moscow Multiple Sclerosis Center: issues of efficacy and adherence to therapy].
    Boĭko AN; Davydovskaia MF; Demina TL; Lashch NIu; Ovcharov VV; Popova NF; Sinbukhova NI; Khachanova NV; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():101-10. PubMed ID: 17172244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A clinical study of multiple sclerosis patients treated with betaferon.
    Manova MG; Kostadinova II; Akabaliev VC
    Folia Med (Plovdiv); 2008; 50(3):24-9. PubMed ID: 19009747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized trial of erhuangfang for relapsing multiple sclerosis.
    Zhou L; Fan Y
    Neurol Res; 2015 Jul; 37(7):633-7. PubMed ID: 25668581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
    Mehrpour M; Akhoundi FH; Delgosha M; Keyvani H; Motamed MR; Sheibani B; Meysamie A
    Neurologist; 2015 Oct; 20(4):57-60. PubMed ID: 26468869
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
    Totolian NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
    [No Abstract]   [Full Text] [Related]  

  • 57. [Betaferon--first experience of application in treatment of multiple sclerosis in Russia].
    Zavalishin IA; Iakhno NN; Zhuchenko TD; Niiazbekova AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(12):24-7. PubMed ID: 9591060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain].
    Rubio-Terrés C; Domínguez-Gil Hurlé A
    Rev Neurol; 2005 Jun 16-30; 40(12):705-10. PubMed ID: 15973634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
    Ghezzi A; Amato MP; Annovazzi P; Capobianco M; Gallo P; La Mantia L; Marrosu MG; Martinelli V; Milani N; Moiola L; Patti F; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Neurol Sci; 2009 Jun; 30(3):193-9. PubMed ID: 19387545
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis.
    Mokhber N; Azarpazhooh A; Orouji E; Khorram B; Modares Gharavi M; Kakhi S; Khallaghi H; Azarpazhooh MR
    Psychiatry Clin Neurosci; 2015 Oct; 69(10):649-57. PubMed ID: 25907350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.